We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma.
- Authors
Song, Pengtao; Xu, Yongcan; Ye, Guochao
- Abstract
Although most differentiated thyroid carcinoma has a clinically favorable prognosis, some of specific types of thyroid cancer (such as anaplastic thyroid carcinoma and advanced papillary thyroid carcinoma) show fatal outcomes and require novel treatments. Immunotherapy is a promising avenue for the treatment of advanced thyroid carcinoma. B7-H3 (B7 homolog 3 protein) and ICAM-1 (intercellular adhesion molecule 1), as two important immune checkpoints (ICPs), is becoming hopeful target spots for immunotherapy. A growing amount of evidence has suggested that B7-H3 and ICAM-1 are upregulated in papillary thyroid carcinoma. However, their expression level in specific types of thyroid cancer remains largely unclear. In the present study, we explored the expression level of B7-H3 and ICAM-1 in different types of thyroid carcinoma. In the groups of the TCGA cohort, both B7-H3 and ICAM-1 mRNA were highly expressed in thyroid carcinoma. Furthermore, the patients with Stage2, 61-80y, Follicular thyroid papillary carcinoma and N0 had lower B7-H3 and ICAM-1 mRNA expression. In the groups of our cohort, PTCs and ATCs showed frequently moderate to strong expression of B7-H3 and ICAM-1 protein expression. The significant relevance of B7-H3 staining score with ICAM-1 staining score was observed in TCGA database and our cohort, which might open avenues for the combination therapy in advanced thyroid cancer.
- Subjects
THYROID cancer; ANAPLASTIC thyroid cancer; DRUG target; PAPILLARY carcinoma; GENE expression; BRAF genes
- Publication
Diagnostic Pathology, 2024, Vol 19, Issue 1, p1
- ISSN
1746-1596
- Publication type
Article
- DOI
10.1186/s13000-024-01504-2